Library Subscription: Guest
Critical Reviews™ in Immunology

Published 6 issues per year

ISSN Print: 1040-8401

ISSN Online: 2162-6472

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.3 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.6 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00079 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.24 SJR: 0.429 SNIP: 0.287 CiteScore™:: 2.7 H-Index: 81

Indexed in

Complement in Antibody-Based Tumor Therapy

Volume 34, Issue 3, 2014, pp. 199-214
DOI: 10.1615/CritRevImmunol.2014009761
Get accessGet access

ABSTRACT

Monoclonal antibodies constitute a major treatment option for many tumor patients. Due to their specific recognition sites in their constant Fc regions, antibodies are able to trigger antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). While the contribution of ADCC to clinical efficacy has been strengthened by observations that patients with favorable F receptor polymorphisms display better response rates to therapeutic antibodies, the contribution of CDC to their clinical efficacy remains controversial. In the background of high expression of complement-regulatory proteins on tumor cells as well as of the fact that some therapeutic antibodies lack the capacity to trigger efficient CDC, strategies have been implemented to improve either the capacity of antibodies to initiate the complement cascade or to interfere with tumor cells' resistance mechanisms. Although both strategies have demonstrated therapeutic benefit in vitro and in murine models, CDC-enhanced antibodies−to the best of our knowledge−have not been clinically tested, and evidence for the potential of CDC-optimizing approaches has yet to be generated in humans. Hence, the potency of complement activation and its impact on the clinical efficacy of therapeutic antibodies still remains to be elucidated in clinical trials encompassing novel complement-enhancing molecules.

CITED BY
  1. Melis Joost P.M., Strumane Kristin, Ruuls Sigrid R., Beurskens Frank J., Schuurman Janine, Parren Paul W.H.I., Complement in therapy and disease, Molecular Immunology, 67, 2, 2015. Crossref

  2. Taylor Ronald P., Lindorfer Margaret A., Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies, Seminars in Immunology, 28, 3, 2016. Crossref

  3. Ramos Theresa N., Arynchyna Anastasia A., Blackburn Tessa E., Barnum Scott R., Johnston James M., Soluble membrane attack complex is diagnostic for intraventricular shunt infection in children, JCI Insight, 1, 10, 2016. Crossref

  4. Derer Stefanie, Cossham Michael, Rösner Thies, Kellner Christian, Beurskens Frank J., Schwanbeck Ralf, Lohse Stefan, Sina Christian, Peipp Matthias, Valerius Thomas, A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells, The Journal of Immunology, 195, 10, 2015. Crossref

  5. Stasiłojć Grzegorz, Österborg Anders, Blom Anna M., Okrój Marcin, New perspectives on complement mediated immunotherapy, Cancer Treatment Reviews, 45, 2016. Crossref

  6. Reis Edimara S., Mastellos Dimitrios C., Ricklin Daniel, Mantovani Alberto, Lambris John D., Complement in cancer: untangling an intricate relationship, Nature Reviews Immunology, 18, 1, 2018. Crossref

  7. Sina Christian, Kemper Claudia, Derer Stefanie, The intestinal complement system in inflammatory bowel disease: Shaping intestinal barrier function, Seminars in Immunology, 37, 2018. Crossref

  8. Olcina Monica M, Kim Ryan K, Melemenidis Stavros, Graves Edward E, Giaccia Amato J, The tumour microenvironment links complement system dysregulation and hypoxic signalling, The British Journal of Radiology, 2018. Crossref

  9. Macor Paolo, Capolla Sara, Tedesco Francesco, Complement as a Biological Tool to Control Tumor Growth, Frontiers in Immunology, 9, 2018. Crossref

  10. Gialeli Chrysostomi, Gungor Bilgi, Blom Anna M., Novel potential inhibitors of complement system and their roles in complement regulation and beyond, Molecular Immunology, 102, 2018. Crossref

  11. Olcina Monica M., Balanis Nikolas G., Kim Ryan K., Aksoy B. Arman, Kodysh Julia, Thompson Michael J., Hammerbacher Jeff, Graeber Thomas G., Giaccia Amato J., Mutations in an Innate Immunity Pathway Are Associated with Poor Overall Survival Outcomes and Hypoxic Signaling in Cancer, Cell Reports, 25, 13, 2018. Crossref

  12. Li Lei, Yang Hong, Li Yan, Li Xiao-Dong, Zeng Ting-Ting, Lin Su-Xia, Zhu Ying-Hui, Guan Xin-Yuan, Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression, Cell Death Discovery, 4, 1, 2018. Crossref

  13. Li Xiang, Lan Xu, Wang Grace, Liu Yi, Zhao Ke, Lu Shan-Zheng, Xu Xiao-Xi, Shi Gang-Gang, Ye Kui, Zhang Bao-Ren, Zhao Yi-Ming, Han Hong-Qiu, Du Cai-Gan, Ichim Thomas E., Wang Hao, Skin Allografting Activates Anti-tumor Immunity and Suppresses Growth of Colon Cancer in Mice, Translational Oncology, 11, 4, 2018. Crossref

  14. Bordron Anne, Bagacean Cristina, Tempescul Adrian, Berthou Christian, Bettacchioli Eléonore, Hillion Sophie, Renaudineau Yves, Complement System: a Neglected Pathway in Immunotherapy, Clinical Reviews in Allergy & Immunology, 58, 2, 2020. Crossref

  15. Fischinger Stephanie, Fallon Jonathan K., Michell Ashlin R., Broge Thomas, Suscovich Todd J., Streeck Hendrik, Alter Galit, A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation, Journal of Immunological Methods, 473, 2019. Crossref

  16. Preisker Sophie, Brethack Ann-Kathrin, Bokemeyer Arne, Bettenworth Dominik, Sina Christian, Derer Stefanie, Crohn’s Disease Patients in Remission Display an Enhanced Intestinal IgM+ B Cell Count in Concert with a Strong Activation of the Intestinal Complement System, Cells, 8, 1, 2019. Crossref

  17. Seguin‐Devaux Carole, Plesseria Jean‐Marc, Verschueren Charlène, Masquelier Cécile, Iserentant Gilles, Fullana Marie, Józsi Mihály, Cohen Jacques H. M., Dervillez Xavier, FHR4‐based immunoconjugates direct complement‐dependent cytotoxicity and phagocytosis towards HER2‐positive cancer cells, Molecular Oncology, 13, 12, 2019. Crossref

  18. Liu Alvin Y., Kanan Adelle D., Radon Tomasz P., Shah Siama, Weeks Mark E., Foster Julie M., Sosabowski Jane K., Dumartin Laurent, Crnogorac-Jurcevic Tatjana, AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting, Oncotarget, 10, 42, 2019. Crossref

  19. Levin Steven D., Evans Lawrence S., Bort Susan, Rickel Erika, Lewis Katherine E., Wu Rebecca P., Hoover Joseph, MacNeil Sean, La David, Wolfson Martin F., Rixon Mark W., Dillon Stacey R., Kornacker Michael G., Swanson Ryan, Peng Stanford L., Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains, Frontiers in Immunology, 10, 2020. Crossref

  20. Elvington Michelle, Liszewski M. Kathryn, Atkinson John P., CD46 and Oncologic Interactions: Friendly Fire against Cancer, Antibodies, 9, 4, 2020. Crossref

  21. Taylor Ronald P., Lindorfer Margaret A., How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2+, Antibodies, 9, 3, 2020. Crossref

  22. Liu Rena, Oldham Robert, Teal Emma, Beers Stephen, Cragg Mark, Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment, Antibodies, 9, 4, 2020. Crossref

  23. O’Brien Rebecca M., Cannon Aoife, Reynolds John V., Lysaght Joanne, Lynam-Lennon Niamh, Complement in Tumourigenesis and the Response to Cancer Therapy, Cancers, 13, 6, 2021. Crossref

  24. Wang Bo, Gallolu Kankanamalage Sachith, Dong Jianbo, Liu Yue, Optimization of therapeutic antibodies, Antibody Therapeutics, 4, 1, 2021. Crossref

  25. Shalapour Shabnam, Karin Michael, The neglected brothers come of age: B cells and cancer, Seminars in Immunology, 52, 2021. Crossref

  26. Y. Liu Alvin, Crnogorac-Jurcevic Tatjana, J. Lai James, Lam Hung-Ming, Antibody Therapy Targeting Cancer-Specific Cell Surface Antigen AGR2, in Advances in Precision Medicine Oncology, 2021. Crossref

  27. Murer Patrizia, Kiefer Jonathan D., Plüss Louis, Matasci Mattia, Blümich Sandra L., Stringhini Marco, Neri Dario, Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin, Journal of Investigative Dermatology, 139, 6, 2019. Crossref

  28. Skarzynski Martin, Niemann Carsten U., Lee Yuh Shan, Martyr Sabrina, Maric Irina, Salem Dalia, Stetler-Stevenson Maryalice, Marti Gerald E., Calvo Katherine R., Yuan Constance, Valdez Janet, Soto Susan, Farooqui Mohammed Z.H., Herman Sarah E.M., Wiestner Adrian, Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy, Clinical Cancer Research, 22, 1, 2016. Crossref

  29. Gehlert Carina Lynn, Rahmati Pegah, Boje Ammelie Svea, Winterberg Dorothee, Krohn Steffen, Theocharis Thomas, Cappuzzello Elisa, Lux Anja, Nimmerjahn Falk, Ludwig Ralf J., Lustig Marta, Rösner Thies, Valerius Thomas, Schewe Denis Martin, Kellner Christian, Klausz Katja, Peipp Matthias, Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody, Frontiers in Immunology, 13, 2022. Crossref

Forthcoming Articles

Identification of a novel five-gene prognostic model for laryngeal cancer associated with mitophagy using integrated bioinformatics analysis and experimental verification Dong Song, Lun Dong, Mei Wang, Xiaoping Gao Function of steroid receptor coactivators (SRCs) in T cells and cancers: Implications for cancer immunotherapy Wencan Zhang, Xu Cao, Hongmin Wu, Xiancai Zhong, Yun Shi, Zuoming Sun Electroacupuncture Alleviates Ischemic Stroke by Activating the mTOR/SREBP1 Pathway Jiawang Lang, Jianchang Luo, Luodan Wang, Wenbin Xu, Jie Jia, Zhipeng Zhao, Boxu Lang KIAA1429 induces the m6A modification of LINC01106 to enhance the malignancy of lung adenocarcinoma cell via JAK/STAT3 pathway Di Xu, Ziming Wang, Fajiu Li Effect of p-estrogen receptor at serine on its function and breast growth Yuan Liang, Junhui Qin, Tiancheng Ma, Tong Yang, Zhenyu Ke, Ruian Wang Mechanistic Insights into Tanshinone IIA in the Amelioration of Post-Thyroidectomy Hypoparathyroidism Xiaoyu Qian, Lin Li, Liang Chen, Chao Shen, Jian Tang MiRNA let-7d-5p alleviates inflammatory responses by targeting Map3k1 and inactivating ERK/p38 MAPK signaling in microglia Fan Fang, Cheng Chen Role of Natural Killer Cells as Cell-Based Immunotherapy in Oral Tumor Eradication and Differentiation Both In Vivo and In Vitro Kawaljit Kaur, Anahid Jewett The Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma Tu Nguyen, Po-Chun Chen, Janet Pham, Kawaljit Kaur, Steven Raman, Anahid Jewett, Jason Chiang Phillygenin alleviated arthritis through the inhibition of NLRP3 inflammasome and Ferroptosis by AMPK Jianghui Wang, Shufang Ni, Kai Zheng, Yan Zhao, peihong zhang, Hong Chang The value of systemic immune-inflammation index and T cell subsets in the severity and prognosis of sepsis Hao Zhou Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain Serum interleukin 6 and ferritin levels are the independent risk factors for pneumonia in elderly patients Hao Yuan, Jing Tian, Lu Wen Exploration of diagnostic markers associated with inflammation in chronic kidney disease (CKD) based on WGCNA and machine learning Qianjia Wu, Yang Yang, Chongze Lin Clinical significance of serum CTRP3 level in the prediction of cardiac dysfunction and intestinal mucosal barrier dysfunction in patients with severe acute pancreatitis Qiang Shao, Lin Sun The protective effect and mechanism of mild hypothermia on pig lung injury after cardiopulmonary resuscitation Jinlin Ren, Fangfang Zhu, Dongdong Sang, Mulin Cong, Shujuan Jiang Exploring mechanism of Zilongjin in treating lung adenocarcinoma based on network pharmacology combined with experimental verification Kang Zhang, Xiaoqun Chen Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Genes Analysis Jian Shen, Minzhe Li Effects of different doses of dexmedetomidine on the prevention of postoperative sleep disturbance and serum neurotransmitter level in patients under general anesthesia Huifei Lu, Fei He, Ying Huang, Zhongliang Wei Identification of key ubiquitination-related genes and their associated with immune infiltration in osteoarthritis based on mRNA-miRNA network Dalu Yuan, Hailiang Shen, Lina Bai, Menglin Li, Qiujie Ye Diagnostic and Prognostic value of peripheral neutrophil CD64 index in elderly patients with community-acquired pneumonia Yan Li, Jing Zhang, Suhang Wang, Jie Cao Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of Head and Neck Squamous Cell Carcinoma Rongjin Zhou, Junguo Wang Downregulation of miR-503-5p promotes the development of pancreatic cancer via targeting cyclin E2 Fei Li, Ying-pei Ling, Pan Wang, Shi-cheng Gu, Hao Jiang, Jie Zhu
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain